Saturday, July 4, 2015

Teva doesn't specify cuts of $1.5 billion to $2 billion

Generic drugmaker Teva said Friday it would cut costs by $1.5 billion to $2 billion over the next several years, but did not specify how many people will lose jobs, what facilities would be closed or whether the savings would flow to the bottom line.

Teva doesn't specify cuts of $1.5 billion to $2 billion

0 comments

Leaders of Teva Pharmaceutical Industries announced financial projections for 2013 and said the company would cut costs by $1.5 billion to $2 billion over the next several years, but did not specify how many people will lose jobs, what facilities would be closed or whether the savings would flow to the bottom line.

In a conference call with stock market analysts, chief executive officer Jeremy Levin said the cost savings would occur mostly in the next three years and some in the two years thereafter. But after repeated questions from analysts about specifics on the cuts and if investors would see the numbers flow to the bottom line, Levin eventually said, "I would just say, 'Wait until next week."

Teva had previously announced that it would hold an investor conference on Dec. 11 in New York. Friday morning's conference call was announced Thursday night.

"Going forward," Levin said, "Teva will look like a very different company than the Teva of the past."

Teva is based in Israel, but has its Americas headquarters in the Philadelphia suburb of North Wales, and other facilities in the area.

Chief financial officer Eyal Desheh said the company expected sales of generic drugs in the U.S. would be "flat," in 2013.

As for the cost-cutting, Desheh said, "This program will touch all the parts of our company, including operations, procurement of raw materials, indirect purchasing, real estate and site management, IT, R&D, marketing materials and activities, all areas of SG&A (sales, administration)."

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter